Khaled Rahal
Khaled Rahal has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Riadh Chargui
Salah Azaiez Institute of Oncology, Surgical Oncology, Tunis, Tunisia
4 shared publications - Farouk Benna
Service de radiothérapie, institut Salah-Azaiez, Tunis, Tunisie
2 shared publications - Hamouda Boussen
Medical Oncology Department, Abderrahmane Mami Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia
2 shared publications - Hatem Bouzaiene
Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia
2 shared publications - Ines Zemni
Department of Surgical Oncology, Salah Azaiez Institute, Tunis, Tunisia
2 shared publications - Lotfi Kochbati
Department or Radiation Oncology, Abderrahmen Mami Hospital, Ariana, Tunisia
2 shared publications
Latest Publications
- Open Access
- 1 November 2021
- Published by BMJ in International Journal of Gynecological Cancer
- Vol. 31 (Suppl 4) , A37.1-A37
EPV019/#309 Ovarian metastases from breast cancer: a series of nine cases
Objectives Development of ovarian metastasis (OM) during the course of primary breast cancer (PBC) is uncommon and associated with poor prognosis. The objective of this study is to review the characteristic clinical and imaging features of OM from PBC. Methods A retrospective study of nine patients treated in our institution, who had documented OM from breast carcinoma between 2005 and 2020. Results At the time of PBC diagnosis, the mean age was 44 (range 31–64). In five cases, the PBC was unilateral. Histological subtypes were invasive ductal carcinoma in five patients and invasive lobular carcinoma in four patients. ER and PR were positive in eight cases. HER2 was positive in two cases. Five patients had locally advanced breast carcinoma. Four patients had synchronous ovarian metastases. Only three patients underwent breast surgery. Main symptoms of OM were pelvic pain and abdominal distension. An elevated CA 125 level was found in seven cases while CA 15–3 level was increased in eight cases. In four cases, pulmonary and bone metastases were simultaneously diagnosed with OM occurrence. All patients underwent ovarian surgery. Seven patients had bilateral OM. Ascites and peritoneal carcinomatosis were seen respectively in six and three patients. Time to occurrence of OM after PBC was a median of 25 months. The median follow-up period after OM assessment was 18 months. Conclusions The evaluation of ovarian lesion years after breast cancer is challenging and rise the possibility of a metastatic lesion. Imaging, serum tumor markers and histology may provide valuable tools in the assessment of ambiguous cases.
- 1 November 2021
- Published by BMJ in International Journal of Gynecological Cancer
- Vol. 31 (Suppl 4) , A37.1-A37
Open AccessEPV019/#309 Ovarian metastases from breast cancer: a series of nine cases
Objectives Development of ovarian metastasis (OM) during the course of primary breast cancer (PBC) is uncommon and associated with poor prognosis. The objective of this study is to review the characteristic clinical and imaging features of OM from PBC. Methods A retrospective study of nine patients treated in our institution, who had documented OM from breast carcinoma between 2005 and 2020. Results At the time of PBC diagnosis, the mean age was 44 (range 31–64). In five cases, the PBC was unilateral. Histological subtypes were invasive ductal carcinoma in five patients and invasive lobular carcinoma in four patients. ER and PR were positive in eight cases. HER2 was positive in two cases. Five patients had locally advanced breast carcinoma. Four patients had synchronous ovarian metastases. Only three patients underwent breast surgery. Main symptoms of OM were pelvic pain and abdominal distension. An elevated CA 125 level was found in seven cases while CA 15–3 level was increased in eight cases. In four cases, pulmonary and bone metastases were simultaneously diagnosed with OM occurrence. All patients underwent ovarian surgery. Seven patients had bilateral OM. Ascites and peritoneal carcinomatosis were seen respectively in six and three patients. Time to occurrence of OM after PBC was a median of 25 months. The median follow-up period after OM assessment was 18 months. Conclusions The evaluation of ovarian lesion years after breast cancer is challenging and rise the possibility of a metastatic lesion. Imaging, serum tumor markers and histology may provide valuable tools in the assessment of ambiguous cases.
- 2 January 2020
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 16 (1) , 77-80
Pure Ductal Carcinoma in Situ in The Male Breast: A Rare Entity
Male breast cancer,ductal carcinoma in situ,treatment
- 2 January 2020
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 16 (1) , 77-80
Pure Ductal Carcinoma in Situ in The Male Breast: A Rare Entity
Male breast cancer,ductal carcinoma in situ,treatment
- Open Access
- 1 December 2019
- Published by Archives of Clinical and Experimental Medicine in ARCHIVES OF CLINICAL AND EXPERIMENTAL MEDICINE
- Vol. 4 (3) , 148-151
Perineal psödo-kontinan kolostomi üzerinde alt rektal karsinom rekürrensinin başarılı tedavisi: Bir olgu sunumu ve literatürün gözden geçirilmesi
Recurrence of lower rectal carcinoma on perineal pseudo-continent colostomy is rarely reported in the literature. It presents a real challenge for the physician. The aim of this case report was to document an exceptional recurrence and how to manage it. A 56-year-old man presented with stage II adenocarcinoma of the lower rectum. He received concomitant chemoradiation followed by abdominoperineal resection with perineal pseudo-continent colostomy. Three years later, he developed a local recurrence of his prior adenocarcinoma, on the perineal pseudo-continent colostomy. He underwent wide excision, followed by reconstruction with a rectus abdominis myocutaneous flap with an inferior pedicle and an oblique skin paddle. He underwent adjuvant chemotherapy. The patient is free of disease with three years follow up. Extended resection should be considered as an initial treatment for locally recurrent rectal cancer.
- 1 December 2019
- Published by Archives of Clinical and Experimental Medicine in ARCHIVES OF CLINICAL AND EXPERIMENTAL MEDICINE
- Vol. 4 (3) , 148-151
Open AccessPerineal psödo-kontinan kolostomi üzerinde alt rektal karsinom rekürrensinin başarılı tedavisi: Bir olgu sunumu ve literatürün gözden geçirilmesi
Recurrence of lower rectal carcinoma on perineal pseudo-continent colostomy is rarely reported in the literature. It presents a real challenge for the physician. The aim of this case report was to document an exceptional recurrence and how to manage it. A 56-year-old man presented with stage II adenocarcinoma of the lower rectum. He received concomitant chemoradiation followed by abdominoperineal resection with perineal pseudo-continent colostomy. Three years later, he developed a local recurrence of his prior adenocarcinoma, on the perineal pseudo-continent colostomy. He underwent wide excision, followed by reconstruction with a rectus abdominis myocutaneous flap with an inferior pedicle and an oblique skin paddle. He underwent adjuvant chemotherapy. The patient is free of disease with three years follow up. Extended resection should be considered as an initial treatment for locally recurrent rectal cancer.
- Open Access
- 23 November 2017
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 15 (1) , 206
Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients
Histologically, node-negative breast cancer generally have a good prognosis. However, 10 to 30% of the cases present local relapses or metastasis. This group of people has high chances of remission if detected early. The aim of this study is to identify financial affordability for developing countries to adjust treatment. We selected 405 patients with histologically confirmed node-negative breast cancer in our institution between January 2001 and December 2003. Patients with metastasis were excluded. The statistical analysis was conducted using SPSS ver. 18 (SPSS, Inc., Chicago, Illinois). The medial age was 51 years old. The medial tumor size was 35.4 mm. Clinically, 67.2% of the patients were staged cT2 and 63.2%, cN1i. Breast conservation was achieved in 41% of cases. In the histologic examination, the medial size was 30 mm. Grade III tumors were found in 50.1% of patients and positive hormonal receptors in 53.4%. The mean number of lymph nodes was 14. Eight patients had neoadjuvant chemotherapy. Adjuvant locoregional radiation and adjuvant chemotherapy were prescribed respectively in 70.6 and 64.4% of cases. 59.7% had adjuvant hormonal therapy. The follow-up showed 17.7% cases of relapse either locally or in a metastatic way in a mean time of 57.4 months. The disease-free survival at 5 years was 82.1%, and the overall survival for the same period was 91.5%. The histologic tumor size and the grade and number of lymph node dissected were shown to be influencing the disease-free survival. Radiation therapy and hormone therapy showed improved disease-free survival and overall survival. Our study found interesting results that may help personalize the treatment especially for patient living in underdeveloped countries, but further studies are needed to evaluate those and more accessible prognostic factors for a more accessible healthcare.
- 23 November 2017
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 15 (1) , 206
Open AccessIdentifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients
Histologically, node-negative breast cancer generally have a good prognosis. However, 10 to 30% of the cases present local relapses or metastasis. This group of people has high chances of remission if detected early. The aim of this study is to identify financial affordability for developing countries to adjust treatment. We selected 405 patients with histologically confirmed node-negative breast cancer in our institution between January 2001 and December 2003. Patients with metastasis were excluded. The statistical analysis was conducted using SPSS ver. 18 (SPSS, Inc., Chicago, Illinois). The medial age was 51 years old. The medial tumor size was 35.4 mm. Clinically, 67.2% of the patients were staged cT2 and 63.2%, cN1i. Breast conservation was achieved in 41% of cases. In the histologic examination, the medial size was 30 mm. Grade III tumors were found in 50.1% of patients and positive hormonal receptors in 53.4%. The mean number of lymph nodes was 14. Eight patients had neoadjuvant chemotherapy. Adjuvant locoregional radiation and adjuvant chemotherapy were prescribed respectively in 70.6 and 64.4% of cases. 59.7% had adjuvant hormonal therapy. The follow-up showed 17.7% cases of relapse either locally or in a metastatic way in a mean time of 57.4 months. The disease-free survival at 5 years was 82.1%, and the overall survival for the same period was 91.5%. The histologic tumor size and the grade and number of lymph node dissected were shown to be influencing the disease-free survival. Radiation therapy and hormone therapy showed improved disease-free survival and overall survival. Our study found interesting results that may help personalize the treatment especially for patient living in underdeveloped countries, but further studies are needed to evaluate those and more accessible prognostic factors for a more accessible healthcare.
- 1 June 2007
- Published by Elsevier in Gynécologie Obstétrique & Fertilité
- Vol. 35 (6) , 536-540
Cancer du sein secondaire après traitement pour maladie de Hodgkin. À propos de sept cas
- 1 June 2007
- Published by Elsevier in Gynécologie Obstétrique & Fertilité
- Vol. 35 (6) , 536-540
Cancer du sein secondaire après traitement pour maladie de Hodgkin. À propos de sept cas
- 1 October 2003
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 7 (5) , 302-307
Tumeurs secondaires après traitement pour maladie de Hodgkin en Tunisie.
- 1 October 2003
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 7 (5) , 302-307
Tumeurs secondaires après traitement pour maladie de Hodgkin en Tunisie.